Transgenic Sertoli Cells as a Vehicle for Gene Therapy

Gene therapy involves the manipulation of genetic material to replace defective or deficient proteins to restore function in disease states. These genes are introduced into cells by mechanical, chemical, and biological approaches. To date, cell-based gene therapy has been hampered by the lack of an...

Full description

Bibliographic Details
Main Authors: Jannette M. Dufour, Paul Gores, Richelle Hemendinger, Dwaine F. Emerich, Craig R. Halberstadt Ph.D.
Format: Article
Language:English
Published: SAGE Publishing 2004-01-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/000000004772664833
id doaj-9a4e0cff3d2641649b6be3c2d45b0bd7
record_format Article
spelling doaj-9a4e0cff3d2641649b6be3c2d45b0bd72020-11-25T03:27:18ZengSAGE PublishingCell Transplantation0963-68971555-38922004-01-011310.3727/000000004772664833Transgenic Sertoli Cells as a Vehicle for Gene TherapyJannette M. Dufour0Paul Gores1Richelle Hemendinger2Dwaine F. Emerich3Craig R. Halberstadt Ph.D.4Surgical-Medical Research Institute, Department of Surgery, University of Alberta, Edmonton T6G 2N8, CanadaDepartment of General Surgery and The Transplant Center, Carolinas Medical Center, Charlotte, NC 28232Department of General Surgery and The Transplant Center, Carolinas Medical Center, Charlotte, NC 28232Sertoli Technologies, Inc., Cranston, RI 02905Department of General Surgery and The Transplant Center, Carolinas Medical Center, Charlotte, NC 28232Gene therapy involves the manipulation of genetic material to replace defective or deficient proteins to restore function in disease states. These genes are introduced into cells by mechanical, chemical, and biological approaches. To date, cell-based gene therapy has been hampered by the lack of an abundant, safe, and immunologically acceptable source of tissue. As an alternative, transgenic animals designed to produce therapeutic proteins could overcome some of the issues facing gene therapy but the problem of immune rejection of the tissue remains. This article reports on recently published work indicating the potential to use transgenic Sertoli cells surviving in an allogeneic host by virtue of their ability to create a locally immunoprivileged environment, thereby providing for the continued delivery of a therapeutic protein to the systemic circulation.https://doi.org/10.3727/000000004772664833
collection DOAJ
language English
format Article
sources DOAJ
author Jannette M. Dufour
Paul Gores
Richelle Hemendinger
Dwaine F. Emerich
Craig R. Halberstadt Ph.D.
spellingShingle Jannette M. Dufour
Paul Gores
Richelle Hemendinger
Dwaine F. Emerich
Craig R. Halberstadt Ph.D.
Transgenic Sertoli Cells as a Vehicle for Gene Therapy
Cell Transplantation
author_facet Jannette M. Dufour
Paul Gores
Richelle Hemendinger
Dwaine F. Emerich
Craig R. Halberstadt Ph.D.
author_sort Jannette M. Dufour
title Transgenic Sertoli Cells as a Vehicle for Gene Therapy
title_short Transgenic Sertoli Cells as a Vehicle for Gene Therapy
title_full Transgenic Sertoli Cells as a Vehicle for Gene Therapy
title_fullStr Transgenic Sertoli Cells as a Vehicle for Gene Therapy
title_full_unstemmed Transgenic Sertoli Cells as a Vehicle for Gene Therapy
title_sort transgenic sertoli cells as a vehicle for gene therapy
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 2004-01-01
description Gene therapy involves the manipulation of genetic material to replace defective or deficient proteins to restore function in disease states. These genes are introduced into cells by mechanical, chemical, and biological approaches. To date, cell-based gene therapy has been hampered by the lack of an abundant, safe, and immunologically acceptable source of tissue. As an alternative, transgenic animals designed to produce therapeutic proteins could overcome some of the issues facing gene therapy but the problem of immune rejection of the tissue remains. This article reports on recently published work indicating the potential to use transgenic Sertoli cells surviving in an allogeneic host by virtue of their ability to create a locally immunoprivileged environment, thereby providing for the continued delivery of a therapeutic protein to the systemic circulation.
url https://doi.org/10.3727/000000004772664833
work_keys_str_mv AT jannettemdufour transgenicsertolicellsasavehicleforgenetherapy
AT paulgores transgenicsertolicellsasavehicleforgenetherapy
AT richellehemendinger transgenicsertolicellsasavehicleforgenetherapy
AT dwainefemerich transgenicsertolicellsasavehicleforgenetherapy
AT craigrhalberstadtphd transgenicsertolicellsasavehicleforgenetherapy
_version_ 1724588418628845568